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Abstract
Background: Infusion of sodium nitrite could provide sustained therapeutic concentrations of nitric oxide (NO) for the
treatment of a variety of vascular disorders. The study was developed to determine the safety and feasibility of prolonged
sodium nitrite infusion.
Methodology: Healthy volunteers, aged 21 to 60 years old, were candidates for the study performed at the National
Institutes of Health (NIH; protocol 05-N-0075) between July 2007 and August 2008. All subjects provided written consent to
participate. Twelve subjects (5 males, 7 females; mean age, 38.869.2 years (range, 21–56 years)) were intravenously
infused with increasing doses of sodium nitrite for 48 hours (starting dose at 4.2 mg/kg/hr; maximal dose of 533.8 mg/kg/hr).
Clinical, physiologic and laboratory data before, during and after infusion were analyzed.
Findings: The maximal tolerated dose for intravenous infusion of sodium nitrite was 267 mg/kg/hr. Dose limiting toxicity
occurred at 446 mg/kg/hr. Toxicity included a transient asymptomatic decrease of mean arterial blood pressure (more than
15 mmHg) and/or an asymptomatic increase of methemoglobin level above 5%. Nitrite, nitrate, S-nitrosothiols
concentrations in plasma and whole blood increased in all subjects and returned to preinfusion baseline values within
12 hours after cessation of the infusion. The mean half-life of nitrite estimated at maximal tolerated dose was 45.3 minutes
for plasma and 51.4 minutes for whole blood.
Conclusion: Sodium nitrite can be safely infused intravenously at defined concentrations for prolonged intervals. These
results should be valuable for developing studies to investigate new NO treatment paradigms for a variety of clinical
disorders, including cerebral vasospasm after subarachnoid hemorrhage, and ischemia of the heart, liver, kidney and brain,
as well as organ transplants, blood-brain barrier modulation and pulmonary hypertension.
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Introduction
Discovered by the late Robert J. Furchgott as an endothelium-
derived relaxing factor [1], nitric oxide (NO) is a gas continuously
synthesized and released from the vascular endothelium [1].
Preclinical studies indicate that NO may be beneficial for the
treatment of experimental heart, liver, kidney and brain ischemia,
as well as pulmonary hypertension [2,3]. Moreover, intra-arterially
delivered NO has been shown to prevent the development of
delayed cerebral vasospasm after subarachnoid hemorrhage
[4,5,6,7,8,9,10] in a primate model and to facilitate treatment of
brain tumors in a rodent model [11]. However, these preclinical
findings have not been translated into effective clinical treatments,
because safe and prolonged delivery of NO at therapeutic levels is
not feasible using available systemic NO donors (nitroglycerin and
nitroprusside) [4,9] as these organic nitrates have unpredictable
pharmacokinetics, rapidly develop tolerance, and when discontin-
ued, often evoke rebound effect unless delivered extravascularly or
locally [12]. Furthermore, it was believed that because of its
chemical properties, NO in the presence of oxyhemoglobin is
rapidly consumed and forms biologically inactive nitrate
[13,14,15]. But, Mark Gladwin and his colleagues [16] showed
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14504that inhalation of NO produced a subtle increase in forearm blood
flow associated with a concomitant increase in nitrite. As nitrite
has forearm artery-to-vein gradients [17], these results suggest that
nitrite is consumed across the vascular bed and is responsible for
vasodilation earlier attributed exclusively to NO [16,17]. Thus, an
increasing body of evidence indicates that nitrite [16,18] is a major
intravascular storage pool for NO [17,19,20,21] and can serve as
an alternative to systemic delivery of NO or nitrates. Recently,
intravenous administration of sodium nitrite was shown to prevent
delayed cerebral vasospasm in a primate model of subarachnoid
hemorrhage [22] and to limit ischemic damage to the heart,
kidneys, liver and brain in animal models, doing so without a
significant drop in blood pressure or other systemic toxicity
[23,24,25].
Despite encouraging preclinical findings related to the use of
sodium nitrite as an NO donor, clinical information regarding the
prolonged intravenous use of nitrite is not available. To determine
the safety, feasibility, and pharmacokinetics associated with a
sodium nitrite infusion, we infused healthy volunteers with
increasing doses of sodium nitrite for up to 48 hours. We
hypothesized that continuous intravenous infusion of sodium
nitrite is a safe method of NO delivery in doses that provide nitrite
blood concentrations in a therapeutic range (1–25 mM) [17,26,27].
The goal of the study was to establish maximal tolerated dose,
defined as the highest dose that does not cause side effects and
dose limiting toxicity defined as the dose that evokes side effects
particularly a drop of blood pressure and/or increase levels of
methemogobin in blood. Details are described in the Materials
and Methods. During infusion, we serially sampled blood for
laboratory analysis to elucidate the NO metabolome.
Results
Subject characteristics
Twelve healthy subjects (5 males, 7 females) were included in
this study. Their mean age was 38.869.2 years (range, 21–56
years). There were 2 Caucasians and 10 African Americans; this
did not reflect a normal population distribution, it was the effect of
the consecutive subject recruitment. Their mean weight was
77.8619 kg (range, 49–115 kg). Preinfusion (baseline) demo-
graphics, sodium nitrite doses, methemoglobin, and NO metabo-
lome data of the study group are presented in Tables 1 and 2.
Sodium nitrite infusion and NO metabolome
We present the results in 3 groups based on the dosing scheme
of sodium nitrite.
Accelerated dosing group (subjects 1–8; subjects 7 and 8 are
presented separately in the maximal tolerated dose and dose
limiting toxicity sections; respectively). The first subject underwent
sodium nitrite infusion at 4.2 mg/kg/hr. Each subsequent subject
received a sodium nitrite concentration double that of the
preceding subject (details described in the Materials and Methods).
Mean arterial blood pressure (Table S1) in this group of subjects
was unaffected, and there was no evidence of toxicity during
infusion until reaching subject 8 (dose, 533.8 mg/kg/hr; see the
dose limiting dose section for details). Thirty minutes after the
initiation of infusion, methemoglobin levels plateaued at 0.9% to
1.3% in subjects 1 through 6 and at 1.8% and 3.1% in subjects 7
and 8; respectively. Nitrite concentrations in plasma, whole blood
and red blood cells increased in a dose- and time-dependent
manner (Table S1). These levels reached a plateau between
20 minutes and 2 hours in all subjects. There was no clear dose- or
time-dependent effect of the sodium nitrite infusion on nitrate
concentrations in plasma or whole blood. However, nitrate
concentrations in red blood cells increased in a dose- and time-
dependent manner before reaching a plateau 12 hours after start
of the infusion and returned to preinfusion levels 12 hours after the
infusion ended. Plasma S-nitrosothiol concentrations reached a
plateau at 6 hours after start of the infusion and returned to
baseline within 12 hours after infusion cessation (Table S1).
Maximal tolerated dose group (subjects 7, 9, and 10)
Subject 7 from the accelerated dosing group and the two
additional volunteers (subjects 9 and 10) were infused at 266.9 mg/
kg/hr. Sodium nitrite infusion did not affect mean arterial blood
pressure in any of these subjects (Figure 1A). Methemoglobin levels
increased gradually, reached a plateau 2 hours after beginning of
the infusion (Figure 1A; maximal level, 1.660.5%), and remained
elevated until 30 minutes after the infusion ended, before
returning to baseline within 1 hour of infusion cessation.
Table 1. Baseline characteristics of healthy subjects.
Subject Number Age Sex Race Weight Kg Dose mg/kg/hr MABP mmHg MetHb %
1 31 M B 98 4.2 95 1
2 56 F B 59 8.3 101 0.7
3 45 F B 86 16.7 95 0.7
4 50 M B 95 33.4 77 0.9
5 42 M B 60 66.8 101 0.7
6 40 F W 49 133.4 71 0.5
7* 34 F B 69 266.9 100 0.7
8 { 47 M W 65 533.8 85 0.5
9* 31 F B 83 266.9 69 0.8
10* 33 M B 87 266.9 85 0.6
11{ 30 F B 115 445.7 100 0.9
12{ 27 F B 68 445.7 86 0.8
Mean 39 F:M W:B 77.8 89 0.7
SD 9 7:5 2:10 19 12 0.2
doi:10.1371/journal.pone.0014504.t001
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1.5 hours after infusion initiation (Figure 1B). Nitrite concentrations
in red blood cells reached a maximum level 24 hours after beginning
of the infusion (Figure 1C). Nitrite concentrations in whole blood
increased from baseline before reaching a plateau 1 hour after
infusion initiation (Figure 1D). Nitrite concentrations in all 3
compartments (plasma, red blood cells and whole blood) returned
to baseline concentrations within 1 hour of infusion cessation.
Nitrate concentrations in plasma increased 12 hours after
infusion initiation (Figure 1B), and reached their highest
concentration 1 hour after infusion cessation. Nitrate concentra-
tions in red blood cells increased 12 hours after infusion initiation,
reaching the highest concentration immediately before cessation of
the sodium nitrite infusion (Figure 1C). Nitrate concentrations in
whole blood increased 8 hours after infusion initiation before
reaching their highest-level 24 hours after infusion initiation
(Figure 1D). Nitrate concentrations in the 3 compartments
returned to baseline within 8 hours after infusion cessation
(Figure 1B–D).
Concentrations of S-nitrosothiols in plasma reached their
highest level at 8 hours after infusion initiation and returned to
baseline within 5 minutes of infusion cessation (Figure 1B).
Dose limiting toxicity group (subjects 8, 11, and 12)
This group included subject 8 (dose, 533.8 mg/kg/hr; Tables 1, 2)
from the accelerated dosing group and two additional subjects that
were infused with a dose of 445.7 mg/kg/hr (66% above the maximal
tolerated dose of 266.9 mg/kg/hr). In this group, mean arterial blood
pressure was decreased by more than 15 mmHg in two subjects, and
the methemoglobin level exceeded 5% in one subject.
Nine hours after infusion initiation in subject 8, the mean
arterial blood pressure dropped by 15 mmHg, and the infusion
was stopped (Figure 2A). The methemoglobin level peaked at
3.1%. Six hours after interrupting the infusion, the infusion was re-
started at half the starting dose (dose, 266.9 mg/kg/hr; Figure 2A).
At that time, nitrite in red blood cells and S-nitrosothiols in
plasma, as well as nitrate in whole blood and red blood cells,
remained elevated. After re-initiation of the infusion, plasma
nitrite concentrations increased rapidly (Figure 2B). At 2.25 hours,
the infusion was stopped because the subject experienced a 20-
mmHg decrease in mean arterial blood pressure (Figure 2A). All
values except nitrite and nitrate in whole blood returned to
baseline concentrations within 12 hours after infusion cessation
(Figure 2A–D).
In subject 11, the methemoglobin level increased above 5%
2 minutes after sodium nitrite infusion cessation (Figure 3A,B). At
the same time, nitrate concentrations in red blood cells and whole
blood reached their highest levels (Figure 3C,D).
In subject 12, mean arterial blood pressure dropped by
20 mmHg 3.2 hours after infusion initiation, and the infusion
was stopped. The methemogobin levels in this subject remained
within normal values (Figure 4A). When the mean arterial blood
pressure dropped in this subject, nitrite in plasma and nitrate in
red blood cells and whole blood reached their highest levels
(Figure 4B–D). In all three instances of dose limiting toxicity the
subjects remained asymptomatic and the effects were transient and
did not require additional intervention.
Other clinical and laboratory analysis
None of the infused nitrite doses resulted in clinical symptoms.
None of the patient complained of headache during or after
sodium nitrite infusion. The initial mean arterial blood pressure
for all 12 subjects was 87610 mmHg, and 91610 mmHg at
12 hours after stopping the sodium nitrite infusion (Table 3).
Table 2. Baseline characteristics of healthy subjects: nitric oxide (NO) metabolome.
Subject
Number
Plasma NO2
mmol/L
Plasma NO3
mmol/L
Plasma SNO
nmol/L
WholeBlood
NO2 mmol/L
Whole Blood
NO3 mmol/L
RBC NO2
mmol/L
RBCNO3
mmol/L
1 0.15 11.1 49.6 0.06 28.27
2 0.07 13.28 35.2 0.23 24.65
3 0.13 11.58 35.2 0.34 14.82
4 0.24 15.41 22.8 0.22 15.23
5 0.13 42.34 28.8 0.41 58.51
6 0.14 43.63 46.3 0.42 62.99
7* 0.11 14.23 30.11 0.28 14.11 0.2 14.11
8 { 0.33 27.22 18.93 0.24 27.37 0.3 23.84
9* 0.52 15.6 17.85 0.35 15.32 0.48 14.19
10* 0.16 12.29 22.77 0.16 40.65 0.39 20.26
11{ 0.93 11.78 28.88 0.03 20.15 0.49 12.32
12{ 0.13 9.13 15.8 0.15 10.26 0.29 8.61
Mean 0.25 18.97 29.35 0.24 27.69 0.36 15.56
SD 0.25 12.1 10.78 0.13 17.56 0.12 5.54
*maximal tolerated dose (MTD).
{dose limiting toxicity (DLT).
MABP, mean arterial blood pressure.
MetHb, methemoglobin.
RBC, red blood cells.
NO2, nitrite.
NO3, nitrate.
SNO, S-nitrosothiols.
SD, standard deviation.
doi:10.1371/journal.pone.0014504.t002
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cally, hematological, metabolic, and functional tests in blood did
not show any changes in the kidney function (electrolytes,
creatinine, uric acid, BUN) or liver functions (alanine transami-
nase, aspartate aminotransferase, direct bilirubin). Also, total
protein, albumin, gamma-glutamyl transpeptidase, lactate dehy-
drogenase and total cholesterol were normal before, during and
after the infusion as well as on follow up visit. The subnormal
levels of urea nitrogen observed in several subjects before the
infusion also remained low during and after the infusion.
The in vitro mammalian chromosomal aberration test (Study
No. AB39MP.341.BTL) was negative in all subjects. At 30 days
follow-up, the subjects remained healthy, and their clinical and
laboratory results were normal. There were no changes in the
regularity of the menstrual cycle within 3 months after infusion.
Nitrite pharmacokinetics
Comparing nitrite the area under the concentration-time curves
(AUC) relative to its corresponding dose (AUC0-last/D) over the
entire dose range (Table 1) suggested that the systemic exposure to
nitrite in plasma and whole blood increased less than proportionally
with increasing doses. The estimated power coefficient (b1) of 0.396
(95% confidence intervals (CIs), 0.248–0.544) for plasma nitrite and
0.309 (95% CIs, 0.162–0.456) for whole blood nitrite (Figure 5A,B),
Figure 1. Clinical and biochemical data for the Maximal Tolerated Dose (MTD) group. This composite graph depicts the mean values and
standard deviations (bars) of: A; mean arterial blood pressure and methemoglobin. B; NO metabolome concentrations in plasma (nitrite, nitrate, S-
nitrosothiols), red blood cells (C; nitrite and nitrate) and whole blood (D; nitrite and nitrate) in three subjects who did not develop nitrite-related
toxicity during sodium nitrite infusion at 266.9 mg/kg/hr [maximal tolerated dose (MTD)] Note that in this group all NO metabolome concentrations
returned to baseline levels within 12 hours after completion of sodium nitrite infusion.
doi:10.1371/journal.pone.0014504.g001
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pharmacokinetics of nitrite. The observed nonlinearity appeared to
be attributed toa dramaticincrease innitrite clearanceupto16-fold
at 12.8 mg/kg or higher, compared with 7.5 mL/min/kg at the
lowestdose of0.2 mg/kginthe study,suggestingthatnitrite ismuch
more rapidly removed from the body at higher doses. The volume
of distribution at steady state also appeared to increase at higher
doses,butthevalueswerehighlyvariableacrossdoses,andthetrend
Figure 2. Clinical and biochemical data for Subject 8 (Dose Limiting Toxicity; DLT). This composite graph depicts: A; mean arterial blood
pressure and methemoglobin; and NO metabolome concentrations in plasma (B; nitrite, nitrate, S-nitrosothiols), red blood cells (C; nitrite and nitrate)
and whole blood (D; nitrite and nitrate) in subject 8 who had a drop of mean arterial blood pressure during sodium nitrite infusion at 533.8 mg/kg/hr
and then again with the half-dose infusion (266.9 mg/kg/hr; MTD) despite 6 hours of rest between the infusions. The baseline values of mean arterial
blood pressure and methemoglobin levels in this subject were 93 mmHg and 0.7%, respectively. He started sodium nitrite infusion at 533.8 mg/kg/hr.
After 8 hours of sodium nitrite infusion, mean arterial blood pressure decreased by 15 mmHg and the infusion was stopped at the 9
th hour. After
6 hours of rest, the infusion was re-started at the half dose (266.9 mg/kg/hr). At this time blood pressure and methemoglobin levels, as well as nitrite
and nitrate concentrations in plasma all returned to baseline levels. But nitrite in red blood cells and S-nitrosothiols in plasma as well as nitrate in red
blood cells and whole blood remained elevated (B–D). Immediately after initiation of the second infusion, nitrite concentration in plasma increased
rapidly. However, nitrate concentrations in plasma, red blood cells, and whole blood remained stable. At 2.25 hours the half-dose infusion was
stopped because of a significant (this time more than 20 mmHg) decrease in blood pressure; methemoglobin barely increased at that time and nitrite
and nitrate concentrations, despite being 2 and 8 times higher than at the beginning of the second infusion, remained well below the highest level
during the first infusion (A–D). The subject remained asymptomatic during and after both infusions. All concentrations, except nitrite and nitrate in
whole blood, returned to normal levels within 12 hours after stopping the infusion.
doi:10.1371/journal.pone.0014504.g002
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nitrite estimated at the maximal tolerated dose was 45.361.0 min-
utes for plasma and 51.4622.6 minutes for whole blood.
Chemiluminescence and gas chromatography-mass
spectroscopy (GC-MS)
To compare the clinical usefulness and reliability of chemilumi-
nescence and GC-MS for measurement of the NO metabolome, the
nitrite concentrations were assessed in plasma and whole blood from
subjects 9, 10, 11 and 12 using both methods. The baseline levels of
nitrite in plasma and whole blood as measured by chemilumines-
cence (Table 2; 0.2560.25 mmol/L, 0.2460.13 mmol/L; respec-
tively) were below the sensitivity of GC-MS (lower level of
quantification [LLOQ] being 0.5 mmol/L). The mean values of
nitrite in plasma during the infusion were 0.6560.67 mmol/L by
chemiluminescence method and 2.4161.99 mmol/L by GC-MS.
The plasma nitrite levels measured by both methods changed in
parallel in a time- and dose-dependent manner. The mean values of
nitrite concentrations in whole blood were also different when
measured by chemiluminescence (0.5860.4 mmol/L) and GC-MS
Figure 3. Clinical and biochemical data for Subject 11 (Dose Limiting Toxicity; DLT). This composite graph depicts: A; mean arterial blood
pressure and methemoglobin and NO metabolome concentrations in plasma (B; nitrite, nitrate, S-nitrosothiols), red blood cells (C; nitrite and nitrate)
and whole blood (D; nitrite and nitrate) in subject 11 who developed significant methemoglobinemia during sodium nitrite infusion at 445.7 mg/kg/
hr. Mean arterial blood pressure remained stable during the infusion. The infusion remained uneventful until 2 and 5 minutes after the infusion
cessation when methemoglobin level increased above 5% (A). However, it decreased during the next 5 minutes and returned to baseline at 8 hours
after stopping sodium nitrite infusion. The subject remained asymptomatic. Within the NO metabolome only nitrite concentrations in plasma and red
blood cells returned to baseline values; plasma nitrate, whole blood nitrite and nitrate, and S-nitrosothiols concentrations in plasma remained higher
than the initial values until the end of the observation interval.
doi:10.1371/journal.pone.0014504.g003
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by chemiluminescence changed in a time- and dose-dependent
manner.
Discussion
We established the maximal tolerated dose (266.9 mg/kg/hr)
and dose limited toxicity (445.7 mg/kg/hr) for long-term intrave-
nous infusion of sodium nitrite. The mean half-life of nitrite was
45.3 minutes for plasma and 51.4 minutes for whole blood, and
was similar to the previously reported value for plasma
(42.1 minutes) [26,27]. The highest level of nitrite in blood of 3
volunteers in the maximal tolerated group was 1.1 mM (range:
0.62 mM to 1.17 mM), which would be within the therapeutic
range according to preclinical and early clinical studies (range
assessed as 1 mMt o2 5mM). [26,27,28]. The highest nitrite blood
Figure 4. Clinical and biochemical data for Subject 12 (Dose Limiting Toxicity; DLT). This composite graph depicts: A; mean arterial blood
pressure and methemoglobin and NO metabolome concentrations in plasma (B; nitrite, nitrate, S-nitrosothiols), red blood cells (C; nitrite and nitrate)
and whole blood (D; nitrite and nitrate) in subject 12 who developed toxicity (significant drop of blood pressure) during sodium nitrite infusion at
445.7 mg/kg/hr. She was the second subject to have a sodium nitrite infusion at this dose. Three hours after initiation of sodium nitrite infusion, her
mean arterial blood pressure decreased by 20 mmHg and the infusion was stopped. At this time her methemoglobin level was 2%, plasma level of
nitrite was several times higher than baseline but nitrate remained unchanged. In the red blood cells, nitrite increased but nitrate remained at
baseline level. Nitrite in whole blood was also several times higher than baseline and nitrate concentration was unchanged compared with baseline.
S-nitrosothiol concentrations in plasma were at 37 nmol/L and well below the peak of 61 nmol/L reached a few hours earlier (A–D). This subject was
observed for an additional 12 hours and remained asymptomatic. Among NO metabolome measurements in this subject, only S-nitrosothiols
remained high 12 hours after stopping the infusion.
doi:10.1371/journal.pone.0014504.g004
Sodium Nitrite Infusion
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1 mM-subject 11, and 1.5 mM in subject 12.
The dose limiting toxicity was restricted to an asymptomatic
increase of methemoglobin and, clinically irrelevant, a transient
decrease of blood pressure. Furthermore, all hematological,
metabolic and functional tests in blood did not show any changes
in the blood chemistry, kidney, and liver functions during and after
the infusion as well as on follow up visit. The nitrite
pharmacokinetics analysis revealed a dramatic increase of nitrite
clearance with increased doses. These findings suggest that
prolonged intravenous infusion of sodium nitrite at doses at and
below the maximal tolerated dose is safe and should assure
therapeutic levels of nitrite.
These results should be valuable for designing human studies to
investigate the utility of sodium nitrite for clinical disorders, which
include cerebral vasospasm after subarachnoid hemorrhage [22],
heart and brain ischemia and reperfusion, blood-tumor barrier
modulation, pulmonary hypertension and organ transplantation
[3,11,23,24,26,29,30,31].
Nitrite as endogenous NO donor
Nitric oxide, also known as endothelium-derived relaxing factor,
is a free-radical gas [1], which exerts biological effects via
activation of soluble guanylyl cyclase, leading to increased
production of cyclic guanylyl monophosphate (cGMP) or via
cGMP-independent pathways [14],[32]. Because of its free radical
properties and extremely high affinity to ferrous iron of heme
moiety, NO also forms nitrate [13], nitrosothiols, nitrosamines,
and iron-nitrosyl compounds, collectively called NO-adducts
(NOx) [33,34] or NO metabolome. Each compound of NO
metabolome has a potential to be a source of NO-related
biological activity [13,15,32,34,35]. For many years it was widely
accepted that in the presence of erythrocytes, NO is rapidly
consumed [14,15], but a seminal report showed that inhalation of
NO produced a subtle increase in forearm blood flow despite
regional inhibition of NO synthase associated with a concomitant
increase in both heme-bound NO [15] and nitrite [16]. As nitrite
has forearm artery-to-vein gradients in near-micromolar concen-
trations [17], these results suggest that nitrite is consumed across
the vascular bed and is responsible for vasodilation that has been
earlier attributed exclusively to NO [16,17]. These findings suggest
that sodium nitrite infusions resulting in near-physiologic local
intravenous nitrite concentrations (1 mmol/L) can provide a
reservoir for intravascular NO, particularly during inhibition of
NO synthase, low oxygen tension, and in the presence of
deoxygenated hemoglobin [17,19,22,35,36] acting as nitrite
reductase [37].
Preclinical study of nitrite as a local, on-demand NO
donor
Low concentrations of nitrite in cerebrospinal fluid during
cerebral vasospasm after subarachnoid hemorrhage [38,39,40]
suggest that decreased NO availability is associated with the
development of cerebral vasospasm [41]. Reversal and prevention
of vasospasm by NO gas solution and by NO donors support this
hypothesis [4,9]. Furthermore, intravenous infusion of sodium
nitrite at 10
26 M opens the brain-tumor barrier similarly to NO
donors [11]. Thus, nitrite is an ‘‘on-demand’’ NO donor with
deoxyhemoglobin acting as a nitrite reductase, especially under
hypoxic conditions [17,19,37]. Similar conditions (i.e., the
Table 3. Characteristics of subjects at 12 hours after cessation of intravenous sodium nitrite infusion.
Subject
Number
Dose mg/
kg/hr
MABP
mmHg MetHb %
Plasma
NO2
mmol/L
Plasma
NO3
mmol/L
Plasma
SNO
nmol/L
Whole
Blood NO2
mmol/L
Whole
Blood NO3
mmol/L
RBC
NO2
mmol/L
RBC
NO3
mmol/L
1 4.2 101 0.5 0.11 6.99 31.21 0.18 19.29
2 8.3 102 0.7 0.06 16.31 34.18 0.14 14.83
3 16.7 88 0.8 0.11 15.25 26.79 0.11 15.05
4 33.4 88 0.6 0.13 15.51 32.91 0.24 23.73
5 66.8 102 0.6 0.24 12.34 28.2 0.39 18.24
6 133.4 80 0.4 0.2 22.78 24.12 0.33 51.09
7* 266.9 96 0.6 0.12 12.58 34.39 0.12 11.07 0.29 7.31
8{ 533.8 91 0.9 0.17 18.52 19.42 0.69 43.79 0.34 21.21
9* 266.9 72 0.9 0.09 11.37 14.58 0.44 28.04 0.32 13.01
10* 266.9 97 0.6 0.11 29.64 18.88 0.33 34.52 0.54 23.4
11{ 445.7 105 1 0.11 33.56 36.57 0.38 51.01 0.37 32.02
12{ 445.7 88 0.8 0.01 7.68 54.98 0.26 18.02 0.20 9.68
Mean 93 0.7 0.12 16.88 29.69 0.3 27.4 0.34 17.77
SD 10 .2 0.06 8.18 10.59 0.17 14.36 0.11 9.42
7*The measurements were assessed at 12 hours after second (half-dose) infusion cessation.
*maximal tolerated dose (MTD).
{dose limiting toxicity (DLT).
MABP, mean arterial blood pressure.
MetHb, methemoglobin.
RBC, red blood cells.
NO2, nitrite.
NO3, nitrate.
SNO, S-nitrosothiols.
SD, standard deviation.
doi:10.1371/journal.pone.0014504.t003
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the subarachnoid space after subarachnoid hemorrhage. There-
fore, we used a long-lasting intravenous infusion of sodium nitrite
after subarachnoid hemorrhage and demonstrated that infusion of
sodium nitrite for 14 days prevented development of vasospasm in
a primate model of subarachnoid hemorrhage [22].
Safety and feasibility of long-term intravenous sodium
nitrite infusion in humans
As the next step, before investigating the treatment of patients at
risk of developing vasospasm after aneurismal subarachnoid
hemorrhage, we established in this study the safety and toxicity of
prolonged intravenous infusion of sodium nitrite in healthy
volunteers. Toxicity was limited to asymptomatic transient decreases
of arterial blood pressure and also asymptomatic increases of
methemoglobin levels above 5%. Nitric oxide metabolome values
returned to baseline levels within 12 hours; the only exception was S-
nitrosothiols of subjects receiving toxicity-evoking doses.
Additional encouraging support of the clinical safety of
prolonged sodium nitrite intravenous infusion was that we did
not observe either tolerance, characteristic for organic nitrates, or
clinically significant rebound effect often reported after discontin-
uation of nitroglycerin or sodium nitroprusside and the plasma
clearance of nitrite was increasing with the dose increase.
Nitrite concentrations increased significantly slower and did not
reach values predicted by preclinical and earlier clinical trials
[26,27]. Moreover, decreased mean arterial pressure was observed
at lower nitrite concentrations than previously reported [17,21].
Our data did not provide reliable answer whether a decrease of
mean arterial pressure during the infusion of high doses of sodium
nitrite was evoked by the presence of nitrite or S-nitrosothiols.
Also, our data do not provide an explanation for the unexpected
increase of methemoglobin levels during infusion of a relatively
low dose of sodium nitrite in one subject.
NO metabolome measurement
We confirmed that the concentrations of nitrite/nitrate and S-
nitrosothiols could be reliably measured by chemiluminescence.
The baseline values of the NO metabolome were within the range
of earlier reported nitrite/nitrate/S-nitrosothiols concentrations in
healthy subjects [17,26,45,46]. The ion trap GC-MS method [47]
provided inconsistent nitrite concentrations in whole blood
samples. Also, the GC-MS lower level of quantification at
0.5 mM was below the baseline levels in our study (Tables 1, 2,
and S1) and that reported by others [28,48].
In conclusion: sodium nitrite intravenous infusion, which can be
performed safely for prolonged intervals, provides levels of NO
that are considered therapeutic. These results should be valuable
for developing studies to investigate new NO treatment paradigms
for a variety of clinical disorders, including cerebral vasospasm
after subarachnoid hemorrhage and ischemia of the heart, liver,
kidney, and brain, as well as organ transplants, blood-tumor
barrier modulation and pulmonary hypertension.
Materials and Methods
Ethics statement
The protocol has been approved by the Combined Neurosci-
ence Institutional Review Board and all subjects provided written
consent to participate. The protocol for this trial and supporting
CONSORT checklist are available as supporting information; see
Checklist S1 and Protocol S1.
Subjects
Healthy volunteers, aged 21 to 60 years old, were candidates for
the study performed at the National Institutes of Health (NIH;
protocol 05-N-0075) between July 2007 and August 2008.
Exclusion criteria
Volunteers with a history or evidence of present or past
hypertension (blood pressure greater than 140/90 mmHg),
hypercholesterolemia (LDL cholesterol greater than 130 mg/
dL) or diabetes mellitus (fasting blood glucose greater than
126 mg/dL) were ineligible. Volunteers who had a history of
smoking within 2 years of study entry, cardiovascular disease,
peripheral vascular disease, coagulopathy, or any other disease
predisposing them to vasculitis or Raynaud’s phenomenon were
excluded. Also, volunteers with red blood cell G6PD deficiency,
or a history of reacting to a medication or other substance
characterized by dyspnea and cyanosis was excluded. Further-
more, volunteers with a baseline blood methemoglobin level
greater than 1% with a blood pressure less than 100/70 mmHg
on the study day and subjects treated with nitrates (e.g.,
nitroglycerin) were excluded.
Figure 5. Nitrite pharmacokinetics in plasma and whole blood.
Dose proportionality of nitrite in plasma (left panel) and in whole blood
(right panel) was assessed using the area under the concentration-time
curves AUC0-last as a function of dose in milligrams. The estimated
power coefficient (b1) for plasma and whole blood nitrite was
significantly less than 1, indicating nonlinear pharmacokinetics of
nitrite. This nonlinearity could be attributed to the increased nitrite
clearance at the higher dose compared with the lowest dose, which
strongly suggests that nitrite is much more rapidly removed from the
body at higher doses.
doi:10.1371/journal.pone.0014504.g005
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All studies were performed in the Intensive Care Unit (ICU) of the
Clinical Center at the NIH. At the time of admission, each subject’s
clinical condition was assessed by the ICU staff and a study
investigator. A full panel of blood and clinical chemistry tests,
including urea nitrogen, alkaline phosphatase, and liver panel as well
as a pregnancy test, were performed. A radial arterial line was placed
for continuous blood pressure measurements. A peripherally inserted
central catheter was placed in one arm and an antecubital intravenous
linewasplaced intheother armunderlocal anesthesia.Thirty minutes
after placement of arterial and venous access lines, the first baseline
measurements of the investigated parameters were performed.
Subject monitoring
Because nitrite’s half-life is short and onset of the expected
effects is relatively brief (less than 30 minutes), the subject’s general
and neurological status was monitored and recorded every 1 to
2 hours for 12 hours after adjustment of a dose or termination of
the infusion (Figure 6). During the entire study, mean arterial
blood pressure, systolic and diastolic blood pressure, and EKG
were continuously monitored. Subjects were also observed for
other possible drug-related reactions. Blood methemoglobin was
measured continuously using a Pulse CO-Oximeter RAD-57m
(Masimo Corp., Irvine, CA).
Blood pressure, methemoglobin and blood samples to assess the
NO metabolome, including nitrite and nitrate in plasma, whole
blood and red blood cells, and the sum of protein and lipid bound
NO (S-nitrosothiols) in plasma were collected directly before the
infusion and then at 0, 2, 5, 10, 20, 30, 60, 90 minutes and 2, 3, 4,
5, 6, 8, 12, 24 and 48 hours (Figure 6) during sodium nitrite
infusion. After the infusion was completed, blood samples were
again collected at the same time intervals, with the last one
collected at 12 hours after cessation of infusion.
During the follow-up visit, 30 days after the sodium nitrite
infusion, blood samples for routine clinical chemistry and blood
count were collected.
Additional blood samples
Additional blood samples were collected just before starting
sodium nitrite infusion to determine baseline parameters for
platelet functions (Dr. J. Lozier, Clinical Laboratory Medicine
Branch, Clinical Center, NIH), genotoxicity (chromosomal
aberration studies; Bioreliance, Rockville, MD). To examine the
influence of sodium nitrite on these measures, blood samples were
collected again at 12 hours after cessation of sodium nitrite
infusion. To assess the potential nitrite influence on the menstrual
cycle, pre- and post-treatment menstrual cycle lengths were
determined by subject reports.
Sodium nitrite dosing
Sodium nitrite (Hope Medical Enterprises, Inc., Scottsdale, AZ)
was formulated at a concentration of 300 mg in 10 mL water. A
starting dose was 4.2 mg/kg/hr infused at 1 nmol/kg/min. It was
predicted that this dose would result in a blood nitrite concentration
of 77 nmol/L [27]. This concentration is well below expected
normal levels (150 nmol/L) [27,49]. Doses were increased on the
basis of an accelerated titration scheme, in which the concentration
of sodium nitrite was doubled for each subsequent subject until
dose-limiting toxicity was reached. Following determination of dose
limiting toxicity, 2 additional subjects were infused at the lower dose
(half of the dose limiting toxicity dose) to expand the cohort to 3
subjects (the maximal tolerated dose group) and the next group of
subjects had the dose increased by 66% (the dose limiting toxicity
group) to define more precisely the toxic dose.
Toxicity criteria
Toxicity related to sodium nitrite infusion was recognized when
mean arterial blood pressure decreased more than 15 mmHg and
lasted longer than 30 minutes or when symptomatic methemo-
globinemia (.5%), shortness of breath, other breathing difficulties,
or cardiovascular symptoms were observed. When toxicity
occurred at a specific dose, the infusion was stopped for 6 hours,
Figure 6. Time schedule of procedures and blood sampling for subjects participating in the safety, feasibility and pharmacokinetic
study of long-term intravenous infusion of sodium nitrite. MICU; Medical Intensive Care Unit. H&P; history and physical. BP; arterial blood
pressure. Mo; a month.
doi:10.1371/journal.pone.0014504.g006
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continued in the study protocol. A blood pressure drop of greater
than 20 mmHg for more than 30 minutes and/or methemoglo-
binemia above 5% and/or onset of clinical/EKG symptoms of
cardio-respiratory problems required terminating the infusion.
Blood sample preparation and assays for NO
metabolome
Three milliliters of peripheral venous blood were drawn for
each sample and immediately divided into 3 Eppendorf tubes, 2
containing 30 mL heparin (1000 U/mL) and 1 containing 250 mL
stabilization solution (Ferricyanide, 12 mM; NEM, 10 mM;
DTPA, 100 mM and 1% NP40 dissolved in nitrite-free Millipore
water) to stabilize nitrite and S-nitrosothiols. The latter, a whole
blood sample, was vortexed and stored immediately on dry ice.
The heparinized blood was centrifuged at 2,500 rpm for
2 minutes (Galaxy Mini centrifuge; VWR International; West
Chester, PA) at the bedside. Plasma was removed, aliquoted,
frozen immediately on dry ice and stored at 280uC until assayed
for NO metabolome. After removal of the buffy-coat, 100 mLo f
stabilization solution was added to each tube containing the red
blood cell pellet of subjects 7 to 12. Each sample was re-vortexed,
allowed to settle for 2 minutes and stored on dry ice, frozen and
preserved. For the nitrite/nitrate measurements, the red blood cell
pellet was removed and washed twice in 20 volumes of phosphate-
buffered saline. Assays were performed in the Surgical Neurology
Branch, National Institute of Neurological Disorders and Stroke at
the NIH (chemiluminescence method, Sievers model 280i NO-
analyzer; Boulder, CO) and by a commercial laboratory (Mass-
spectroscopy method; Biopharmaceutical Research Inc.; Vancou-
ver, BC, Canada).
Ozone-based chemiluminescent assays
A stock solution of I3-NO reduction solution was prepared daily
and 7 mL was poured into a glass purge vessel. Helium gas was
bubbled under a constant pressure through the purge vessel,
through 15 mL of 1M NaOH and then into the chemiluminescent
NO analyzer (Sievers Model 280i NO analyzer, Boulder, CO),
which can detect upwards of 1 pmol of NO gas. The following
chemicals were placed in the purge vessel: 7 mL of glacial acetic
acid, 2 mL of distilled water mixed with 111 mg of KI with
addition of 0.072 g iodine (to yield a concentration of about 20–
30 mM) and 50 mL antifoaming agent. Serial injections of S-
nitrosoglutathione and nitrite were used for 4 hours to document
the stability of the I3-stock solution exposed to air. There was no
decrease in NO release from nitrite and S-nitrosothiols during this
time period. This allowed for changing the reagent before each
injection of the hemoglobin solutions and removed variability
produced by increasing protein concentrations and foaming. NO
release from S-nitrosothiols was eliminated by treating the samples
with mercuric chloride (HgCl2, 5 mM) for two minutes. To
specifically identify nitrite versus S-nitrosothiol, samples were
incubated for three minutes with and without (9:1, v/v; 5 wt./
vol.%) acidified sulfanilamide, vortexed and reacted in the I3-
reductant. The difference of sample concentrations treated with
acidified sulfanilamide plus HgCl2 and concentration of samples
treated with acidified sulfanilamide alone represents the concen-
trations of S-nitrosothiols.
To reduce foaming during analysis of nitrite and nitrate levels in
plasma, samples were treated with a 1:1 volume of ice-cold
methanol and centrifuged at 17,9006g and 5uC for 5 minutes
[36]. Nitrate was measured by reduction in vanadium (III) at
90uC; the following chemicals were mixed: 1 M hydrochloric acid
(12 mL), vanadium chloride (0.8 g), distilled water (88 mL) and
antifoaming agent (1 mL).
Gas chromatography-mass spectroscopy (GC-MS)
method
For validation and to compare the methods, 4 subjects (doses 7
and 7.1) had nitrite concentrations measured using mass
spectroscopy. Details of the method used by Biopharmaceutical
Research Inc. (Vancouver, BC) are protected by a patent. But
generally the GC-MS method uses pentafluorobenzyl bromide for
a sole derivatization of the blood sample.
15N-labeled nitrite is an
internal standard and after analytical processes,
14N and
15N
nitrite anions are separated in the mass spectrometer allowing for
measurement of nitrite concentration in the sample with sensitivity
of 22 fmol [45]. Previous baseline plasma nitrite levels measured
by the GC-MS method in healthy volunteers were 1.8 mM [50].
Pharmacokinetic analysis
Individual nitrite concentration versus time profiles were
analyzed using WinNonlin (version 5; Pharsight Corp., Mountain
View, CA) to obtain pharmacokinetic parameters such as the area
under the concentration-time curves up to the last sampling point
(AUC0-last), dose-normalized AUC0-last (AUC0-last/D), clearance
(CL), volume of distribution at steady-state (Vss), and terminal
half-life. Two subjects who experienced toxicity were excluded
from the pharmacokinetic analysis. Nitrite concentrations in
plasma and in whole blood were used in the analysis without the
endogenous baseline subtraction. Dose proportionality of nitrite
pharmacokinetics was assessed by a regression analysis using a
power model (e.g., AUC=b0?Doseb1), which required 95%
confidence intervals (CIs) of the power coefficient (b1), including 1,
to demonstrate proportionality of the system (i.e., linear pharma-
cokinetics) [51].
Statistical analysis
The strategy of this study was to establish the toxicity profile of
prolonged intravenous infusion of sodium nitrite in healthy
subjects. To achieve this goal, we analyzed blood pressure changes
and blood nitrite, nitrate, S-nitrosothiols and methemoglobin
levels of each subject before the infusion, during and after the
infusion to determine the safe dose for future trials. Data are
presented as mean value 6 standard deviation (SD).
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